QUANTA INC
QUANTA INC (QNTA): 5 pipeline candidates · ~1 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.4 months
D/E -1.01 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for QUANTA INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$8K
Quarterly Burn
$249K
Runway
1.4 mo
Revenue
$67K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| escozine | Preclinical |
| muscle rub | Approved |
| qtx3034 | Phase 1 |
| qtx3046 | Phase 1 |
| qtx3544 | Phase 1 |
Frequently asked questions
How many drug candidates are in QUANTA INC's pipeline?
QUANTA INC (QNTA) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is QUANTA INC's lead drug candidate?
QUANTA INC's most advanced tracked candidate is escozine (Preclinical) for Cancer.
What is QUANTA INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, QUANTA INC has approximately 1.4 months of cash runway.
Get the full picture on QUANTA INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.